Market Research Report
Asia Pacific Cystic Fibrosis Therapeutics Market Forecast 2020-2028
|Published by||Inkwood Research||Product code||927062|
|Published||Content info||104 Pages
Delivery time: 2-3 business days
|Asia Pacific Cystic Fibrosis Therapeutics Market Forecast 2020-2028|
|Published: March 2, 2020||Content info: 104 Pages||
The cystic fibrosis therapeutics market of Asia Pacific is estimated to record a CAGR of 9.58% during the projected period of 2020-2028.The rising research and development activities in terms of novel cystic fibrosis therapeutics are anticipated to create lucrative opportunities in the future.
In order to analyze the scope of the Asia Pacific cystic fibrosis therapeutics market further, the region is divided into Japan, Vietnam, Australia & New Zealand, India, Thailand, South Korea, Indonesia, China, and the rest of Asia Pacific that includes Malaysia, Nepal, Singapore, Bangladesh, etc. In the South Korean population, CF is extremely rare, though the disorder is most frequently seen in Caucasians. South Korea's health expenditure increased by 9.4% in 2018 as compared to 2017, according to the OECD Health Statistics of 2019. These factors are expected to influence the market at a steady rate. In countries like Indonesia, CF is rarely observed as per an article. The problem of under-diagnosis in countries can be due to poverty-related problems because of which CF fails to thrive, and therefore driving the market at a stable growth.
In Vietnam, few incidences of severe hereditary chronic lung disorders are expected in the country. Due to the low incidences of CF, the market is anticipated to grow at a lower rate. In Nepal, there is a prevalence of the metabolic disease as per the NCBI article. There is some government deliberation for the high incidence of congenital disorders, but disorders due to enzymatic deficiencies have not been considered for timely diagnosis and intervention. In Singapore, CF is an uncommon disease. In countries like Malaysia, 16 patients were confirmed to have CF from 1987 to 2003. These factors are estimated to propel the market in the rest of the Asia Pacific region.
F. Hoffmann-La Roche Ltd, Abbott Laboratories, Allergan PLC, Pfizer Inc, Agilent Technologies, Inc, etc. are some of the prominent companies in the market.
Our report offerings include: